← Eichor
Study identifier: NCT06085664 Synced from ClinicalTrials.gov · July 30, 2026
● Recruiting

A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

Condition: Prostate Cancer · Radical Prostatectomy  ·  Sponsor: M.D. Anderson Cancer Center

PhasePhase 1/Phase 2
Planned participants42
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

To learn about the safety and effects of a drug called REGN5678 when it is given to patients with high-risk prostate cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Sumit Subudhi, MD, PHD  ·  (713) 792-2830  ·  sksubudhi@mdanderson.org

Sumit Sumit, MD, PHD  ·  (713) 792-2830  ·  sksubudhi@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

M D Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06085664